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Abstract 
 
Cadmium (Cd) is an environmental pollutant that has been associated with cardiovascular disease in 
populations, but the relationship of Cd with hypertension has been inconsistent. We studied the association 
between urinary Cd concentrations, a measure of total body burden, and blood pressure in American 
Indians, a US population with above national average Cd burden. Urinary Cd was measured using 
inductively coupled plasma mass spectrometry, and adjusted for urinary creatinine concentration. Among 
3714 middle-aged American Indian participants of the Strong Heart Study (mean age 56 years, 41% male, 
67% ever-smokers, 23% taking antihypertensive medications), urinary Cd ranged from 0.01 to 78.48 μg g-
1 creatinine (geometric mean=0.94 μg g-1) and it was correlated with smoking pack-year among ever-
smokers (r2=0.16, P<0.0001). Participants who were smokers were on average light-smokers (mean 10.8 
pack-years), and urinary Cd was similarly elevated in light- and never-smokers (geometric means of 
0.88 μg g-1 creatinine for both categories). Log-transformed urinary Cd was significantly associated with 
higher systolic blood pressure in models adjusted for age, sex, geographic area, body mass index, smoking 
(ever vs never, and cumulative pack-years) and kidney function (mean blood pressure difference by lnCd 
concentration (β)=1.64, P=0.002). These associations were present among light- and never-smokers 
(β=2.03, P=0.002, n=2627), although not significant among never-smokers (β=1.22, P=0.18, n=1260). Cd 
was also associated with diastolic blood pressure among light- and never-smokers (β=0.94, P=0.004). 
These findings suggest that there is a relationship between Cd body burden and increased blood pressure in 
American Indians, a population with increased cardiovascular disease risk. 
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Introduction 
Hypertension is a common clinical condition contributing substantially to poor health 
outcomes, including cardiovascular disease (CVD) and mortality1. Hypertension risk varies 
by age, sex, lifestyle and behaviors, and increasing evidence suggests that blood pressure is 
influenced by toxic metal environmental pollutants including cadmium (Cd)2–4. Experimental 
evidence associates Cd to endothelial dysfunction, oxidative stress, atherosclerosis, 
hypertension, and kidney dysfunction5–9. These data are supported by research demonstrating 
a relationship between Cd body burden and CVD in populations9–11. However, the 
epidemiology evidence for association of Cd with hypertension has been inconsistent2, 4, 12–19. 
Little research has been done in populations with low-to-moderate Cd exposure for 
associations with increased systolic and diastolic blood pressures. Blood Cd but not urine Cd 
was associated with increased blood pressure in the National Health and Nutrition 
Examination Survey (NHANES) II (1976–1988)2 and NHANES 1999–200413. A prospective 
study in Belgium showed associations of changes in blood Cd levels with diastolic blood 
pressure among women12. However, a Croatian study showed associations of urinary but not 
blood Cd with diastolic blood pressure17. These studies varied on the choice of Cd 
measurement (blood, urine, nails), study design and definition of outcomes. In addition, the 
relationship between Cd and blood pressure is complicated by the fact that smoking, a major 
source of Cd exposure in populations, is associated with Cd levels but also independently 
associated with hypertension20–24. 
American Indians suffer disproportionally from hypertension-related morbidity and CVD25, 26. 
Prior research in American Indian communities from the Strong Heart Study (SHS) has 
demonstrated an association of Cd burden with incident CVD and mortality10. Middle-aged 
American Indians recruited from the same communities have higher Cd body burden 
compared to national averages from individuals 35 year-old or older from the Third National 
Health and Nutrition Examination Survey (NHANES III) 10, 27. Therefore, American Indians 
are a population at risk of diseases related to Cd toxicity. 
We studied the association of Cd body burden, as measured in urine, with blood pressure and 
hypertension in SHS American Indians. Urinary Cd represents Cd concentrations in the renal 
cortex and has a half-life of decades, representing a suitable biomarker for cumulative Cd 
exposure or body burden28. Because environmental exposures are amenable to public health 
interventions, this research could inform on the Cd-related burden of hypertension and its 
complications in this population. 
  
Methods 
SHS design and population 
The SHS recruited a population based sample of 4,545 unrelated tribal members 45 year or 
older without regard to disease status from 13 tribal communities in Arizona, Oklahoma and 
North and South Dakota29. This study uses data from a clinical visit in 1989–91, which is the 
SHS visit that has measures of urinary cadmium. During the clinical visit, information on 
demographic characteristics (age, sex, education), lifestyle/behaviors (including smoking 
initiation, duration and quantity), and medical history were obtained through interviews. 
Physical exams included anthropometrics (body mass index [BMI], waist and hip girth) and 
blood pressure. Resting sitting blood pressure was measured in the brachial artery three 
consecutive times by trained personnel using a calibrated mercury column 
sphygmomanometer and size-adjusted cuff, and the last two measures were averaged. 
Participants were instructed to bring all medications taken regularly, including both 
prescribed and over-the-counter. All medications were categorized according to the American 
Hospital Formulary Service Pharmacologic-Therapeutic Classification System and 
summarized by therapeutic class as previously described 30. A fasting blood sample and urine 
samples were obtained for biomarker measures, which were assayed using standard methods. 
The SHS/SHFS protocols were approved by the Indian Health Services Institutional Review 
Board, by Institutional Review Boards of all Institutions and by the Indian communities29, 31. 
All participants gave informed consent for participation. 
From the initial sample, we excluded individuals with kidney failure defined as on dialysis or 
receiving a transplant, missing covariates or phenotypes, or urinary Cd measures. The final 
dataset included 3,714 SHS participants for whom urinary Cd measures were available. 
Urinary cadmium measurements. 
Cd was measured in spot urine samples (stored at -80°C) using inductively coupled plasma 
spectrometry32. The analytic methods and quality control (QC) criteria have been previously 
described32. The limit of detection was 0.0015 μg/L. In one participant where Cd was below 
the limit of detection (0.03% of the total sample), the concentration was imputed as the limit 
of detection divided by the square root of two32. The intra-assay and inter-assay coefficients 
of variation for Cd in the SHS were 1.3% and 8.7%, respectively. To account for urine 
dilution, urine Cd concentrations are expressed in μg per g of urine creatinine. Urine 
creatinine was measured by an alkaline picrate method. 
Blood pressure outcomes 
The main outcomes assessed in this study are quantitative blood pressure traits of systolic and 
diastolic blood pressures. For hypertensive individuals taking antihypertensive medications, 
measured blood pressure is expected to be lower than if not treated. Adjusting for 
hypertension treatment as a covariate is not recommended, as it has shown to shrink 
estimated effects and reduce power in simulation studies33. Therefore, we added 10 and 15 
mm Hg to measured systolic and diastolic blood pressures, respectively, for individuals 
reporting taking blood pressure-lowering medications as previously described34, 35. 
Hypertension was defined by a systolic blood pressure of 140 mm Hg or higher, or a diastolic 
blood pressure of 90 mm Hg or higher, or use of antihypertensive drugs36. 
Covariates and definitions 
Urinary Cd levels and blood pressure have been shown to vary by age, sex, BMI and kidney 
function. Smoking is a source of Cd exposure and a potential confounder. All these covariates 
were included in models, in addition to variables to account for Cd variation in geographic 
regions. We also tested other variables including education (less than high-school versus 
high-school or higher degree) which was not a significant predictor in models. Kidney 
function was estimated using the estimated glomerular filtration rate (eGFR) derived from the 
equation developed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). 
The equation is based on serum creatinine, age, sex, and race/ethnicity data37. Chronic 
kidney disease (CKD) was defined by and an eGFR<60 ml/min/1.72 m2. 
Statistical analyses 
Urinary Cd-to-creatinine ratio was right-skewed and the data was natural log-transformed 
(lnCd). Geometric means, medians and percentiles of urinary Cd were also estimated. We 
first examined the association of lnCd with prevalent systolic and diastolic blood pressure 
traits in SHS participants using linear regression models. Models were adjusted for age, age2, 
sex, age-by-sex interactions, BMI and geographical location (Arizona, North and South 
Dakotas, Oklahoma), and eGFR (continuous). We adjusted for smoking quantity and 
intensity using a variable for never vs ever users and cumulative smoking dosage (pack-
years), and also performed analysis in strata of ever versus never smoking. We also examined 
the association of lnCd with blood pressure among never smokers and light smokers (<10 
pack-years). To examine non-linear effects of Cd on blood pressure, we tested the association 
with blood pressure and hypertension within quartiles of Cd distribution using the lower 
quartile as referent. In secondary analyses, we examined the associations among current 
smokers, and if associations were modified by sex or changed when excluding individuals 
taking antihypertensive medications, given prior research suggesting confounding effects of 
anti-hypertensive medications. We also tested Cd associations with hypertension. Statistical 
tests were two sided with significance set at P<0.05. 
  
Results 
Among 3,714 SHS participants the mean age was 56 years, 41% were men and 67% were 
ever-smokers (Table 1). Thirty-eight percent of participants had hypertension, and 23% were 
on an anti-hypertensive medication. Urinary Cd ranged from 0.01 to 78.48 μg/g (geometric 
mean=0.94 μg/g) with a higher average among ever-smokers and current smokers than never-
smokers. Urinary Cd was correlated with smoking pack-year among ever-smokers 
(r2=0.16, P<0.0001). On average, SHS participants were light smokers (mean 10.8 pack-
years), but Cd levels were also elevated among light or never-smokers (Table 1, Figure 1). 
Ten percent (N=370) participants had an eGFR <60 ml/min/1.72 m2 but the mean urinary Cd 
concentration was similar among these individuals and those with an eGFR≥60 ml/min/1.72 
m2. 
In cross-sectional analysis, urinary lnCd was significantly associated with higher systolic 
blood pressure in models adjusted for age, sex, geographic area, BMI and smoking (ever vs. 
never, and cumulative pack-years) (β representing the mean blood pressure difference by unit 
of lnCd concentration=1.11, standard error [SE]=0.54, P=0.037, n=3,714) (Table 2, Model 
2). These estimates were stronger when further adjusting for kidney function (β=1.64, 
SE=0.54, P=0.002, Table 2, Model 3) or when excluding individuals taking antihypertensive 
medications (β=1.57, SE=0.54, P=0.004) (Table 2). The interaction by sex was not 
significant (P=0.82). The association of urinary lnCd with blood pressure among current 
smokers was not significant in fully adjusted models (Table 2). 
Among never-smokers, the adjusted estimates of effect for lnCd levels on blood pressure 
were consistent with that observed among smokers, although not significant 
(β=1.22, P=0.18, Table 2, Model 3). Because never smokers and light smokers (≤10 pack-
years) had similar low urinary Cd concentrations (Figure 1), we also performed a sensitivity 
analysis combining never-smokers and light smokers, for which lnCd association with 
systolic blood pressure showed even stronger estimates (β=2.03, P=0.002, Table 2, Model 3). 
These findings suggest that a relationship exists between Cd and blood pressure even when 
there is minimal confounding by smoking. 
The association of lnCd with diastolic blood pressure was concordant in direction as 
compared to systolic blood pressure, although it was not statistically significant (Table 2, 
Models 2 and 3). However, there was a significant association of urinary Cd concentration 
with diastolic blood pressure among never-smokers and light-smokers (P=0.004, Table 2, 
Model 3). 
In adjusted models, systolic blood pressure increased across quartiles of Cd concentrations 
(P=0.029), while diastolic blood pressure was unchanged (Figure 2, supplementary Table 1). 
In secondary analysis, lnCd was not significantly associated with hypertension (Table 3) but 
there was a trend for increased odds of hypertension in the upper quartile of Cd distribution 
compared to the lower quartile (Figure 2, Supplementary Table 2). 
  
Discussion 
Adolescent and young adult SHS American Indians have a high prevalence of hypertension 
(15%) and pre-hypertension (35%), which has been attributed to obesity and metabolic 
conditions38. This population has above national average Cd body burden and is at risk for 
Cd-related health conditions. The main contribution of our study is the association findings 
between urinary Cd concentrations and elevated systolic blood pressure among middle-aged 
American Indians. These associations were present when adjusting for smoking exposure, 
and among individuals who were light- or never-smokers for increased systolic and diastolic 
blood pressures. Importantly, as tobacco smoke is a source for Cd, we did observe a 
correlation between urinary Cd and smoking pack-year among ever-smokers 
(r2=0.16, P<0.0001). A prior study has also shown a stronger association with blood pressure 
among never-smokers compared to ever-smokers13, suggesting that the effect of Cd on blood 
pressure is unrelated to other smoking toxicants. 
The potential toxic role of Cd as a risk factor for hypertension has not been highlighted in 
clinical guidelines for blood pressure36, 39. Prior population studies have shown inconsistent 
associations between Cd and blood pressure for low-to-moderate Cd exposure2, 4, 12–19. Some of 
these inconsistencies can be explained by differences in populations, study design, 
measurements of Cd (blood vs. urine) and potential sources of Cd. In NHANES III, the 
urinary Cd geometric mean was 0.36 μg/g for individuals 35 years or older27 compared to 
0.88 μg/g among never-smokers American Indians in our study. In addition, most smokers in 
our study were light-smokers (mean 8.8 to 10.8 pack-years). These findings suggest other 
sources of Cd exposure in this population (e.g. food or water) and a potential role for Cd 
source on these outcomes, for example, by exposing to other toxins or risk factors that 
augment Cd toxicity. The sources of Cd and these additional risk factors will need to be 
further evaluated in this population. 
Urinary Cd concentrations have decreased between 1988 and 2008 in the U.S., in parallel 
with declining smoking rates and changes in exposure to tobacco smoke27. However, it is 
unknown if Cd exposure is decreasing in American Indians. Urine levels of Cd correlate with 
increased renal cortex Cd concentration, a major site of Cd accumulation in the body40, and 
thus reflect total body burden. Cd has been associated with kidney dysfunction2 but we did 
not find differences in urinary Cd concentrations among individuals with and without CKD in 
our study. However, adjusting for kidney function strengthened the associations between Cd 
and systolic blood pressure (P=0.002) highlighting the importance of adjusting for 
physiologic functionality. 
Our study is limited to cross-sectional Cd-blood pressure associations, although urinary Cd is 
considered a biomarker of lifetime body burden as compared to blood Cd concentrations28. 
We used a constant to account for blood pressure lowering medications, but our sensitivity 
analysis excluding treated individuals did not show substantial changes of findings. Cd was 
associated with small increases in blood pressure and not with hypertension in our study. 
However, at population level, these small increases in blood pressure have shown to have a 
large impact on CVD events1 and our ultimate goal is to focus on population prevention 
measures. We are currently examining these associations using prospective data. Future 
studies should focus on the interplay of environmental and genetic factors in the Cd-blood 
pressure associations. For example, genome wide association studies have identified 
associations of the SLC39A8 gene with hypertension34. This gene encodes a zinc transporter 
and main carrier of Cd into cells in humans. A recent study has shown the contribution of 
genetic variability to arsenic-associated longitudinal increases in blood pressure41. These and 
our findings suggest a potential causal role of Cd and other metals in the occurrence of 
hypertension. 
In summary, we identified significant associations between urinary Cd and increased blood 
pressure in American Indians, independent of smoking exposure. These findings suggest a 
role for low to moderate Cd burden in increased blood pressure. If confirmed in other studies, 
our findings may have implications for public health promotion and policies in relation to 
exposure to Cd and potentially to other toxic metals. 
  
What is known about topic Cd is an environmental pollutant implicated in 
reproductive, cancer and cardiovascular disease 
health outcomes, but the association with 
hypertension has been inconsistent. The main source 
of Cd exposure is through smoking, which is 
preventable. 
What this study adds This study identified a relationship between long-
term Cd body burden, as measured in urine, with 
increased blood pressure in American Indians, a 
population with above national average Cd burden 
and increased cardiovascular disease risk. The 
associations were independent of smoking, 
suggesting other sources of Cd exposure. These 
findings have implications for public health 
promotion and policies in relation to exposure to Cd 
and potentially to other toxic metals. 
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Tables 
Table 1 
Baseline characteristics of Strong Heart Study participants 
Characteristics Strong Heart Study (n=3,714) 
Mean age, years 56.2 (8.0) 
Men, % 40.6 
Education <12 years 47.4 
Mean systolic blood pressure, mm Hg 127.2 (19.3) 
Mean diastolic blood pressure, mm Hg 76.8 (10.2) 
Mean body mass index, kg/m2 30.9 (6.3) 
Hypertension, % 38.4 
Hypertension treatment, % 23.1 
Ever smoker, % 67.0 
Mean smoking, pack-years 10.8 (18.2) 
Mean eGFR, ml/min/1.73m3 82.5 (21.7) 
Urinary Cd overall, μg/g creatinine* 0.94 (0.92, 0.96) 
Urinary Cd ever-smokers, μg/g creatinine* 0.97 (0.95, 0.998) 
Urinary Cd current-smokers, μg/g 
creatinine* 
1.14 (1.010, 1.18) 
Urinary Cd never-smokers, μg/g creatinine* 0.88 (0.84, 0.91) 
Numbers are mean (standard deviation) unless stated. eGFR, estimated glomerular filtration rate. 
*geometric mean and 95% confidence intervals 
Table 2: Association of urinary Cd with systolic and diastolic blood pressure in the Strong Heart Study 
Trait/Models 
Model 1 Model 2 Model 3 
Mean blood pressure difference 
by LnCd levels (SE) 
P 
Mean blood pressure difference 
by LnCd levels (SE) 
P 
Mean blood pressure difference 
by LnCd levels (SE) 
P 
Overall sample (n=2714) 
Systolic Blood Pressure −0.01 (0.52) 0.98 1.11 (0.54) 0.037 1.64 (0.54) 0.002 
Diastolic Blood Pressure −0.62 (0.27) 0.02 0.05 (0.28) 0.85 0.30 (0.28) 0.29 
Current smokers (n=1,272) * 
Systolic Blood Pressure −0.77 (0.93) 0.41 0.84 (0.96) 0.38 1.38 (0.97) 0.16 
Diastolic Blood Pressure −1.13 (0.51) 0.03 −0.16 (0.53) 0.77 0.16 (0.53) 0.77 
Light- and never-smokers (n=2,627) 
Systolic Blood Pressure 1.01 (0.63) 0.11 1.57 (0.64) 0.01 2.03 (0.64) 0.002 
Diastolic Blood Pressure 0.37 (0.32) 0.25 0.75 (0.33) 0.02 0.94 (0.33) 0.004 
Never smokers (n=1260) ** 
Systolic Blood Pressure 0.57 (0.91) 0.63 0.85 (0.91) 0.93 1.22 (0.91) 0.18 
Diastolic Blood Pressure 0.32 (0.46) 0.7 0.51 (0.46) 0.27 0.66 (0.46) 0.15 
Among individuals not taking blood pressure medications (n=2,856) 
Systolic Blood Pressure 0.35 (0.52) 0.5 1.41 (0.53) 0.008 1.57 (0.54) 0.004 
Diastolic Blood Pressure −0.55 (0.28) 0.05 0.05 (0.29) 0.86 0.16 (0.29) 0.58 
Model 1, adjusted for age, sex, geographic area; Model 2, additionally adjusted for BMI and smoking (ever vs. never, and cumulative pack-years); Model 3, Model 2 with 
additional adjustments for eGFR; 
*same models except for not adjusting for ever smoking; 
**same models except for no adjustments for ever smoking or pack-years. 
  
Table 3: Association of urinary Cd with hypertension 
Trait/Models 
 Model 1 Model 2 
n cases/total Odds ratio (95% CI) Odds ratio (95% CI) 
Hypertension 1,429/3,714 0.91 (0.82, 1.02) 1.08 (0.96, 1.22) 
Model 1, minimally adjusted model for age, sex and geographic region; Model 2, adjusted for age, sex, geographic area, BMI, smoking (ever vs. never, and cumulative pack-
years) and eGFR. Urinary cadmium/creatinine was log-transformed for analyses, see text. 
  
Figure Legends 
Figure 1: Urinary Cd concentrations by smoking heaviness (pack-years) in the SHS. 
Figure 2: Mean systolic and diastolic blood pressure values and odds ratios of hypertension by quartile of Cd concentrations. The corresponding 
values of Cd for each quartiles are: Q1: < 62 μg/g; Q2: 0.62 to 0.93 μg/g; Q3: 0.94 to 1.45 μg/g; Q4: > 1.45 μg/g. 
